Polyseq Biotech

Polyseq Biotech was founded in 2021. Based on the principle of biological nanopore DNA sequencing, the company leverages its self-developed nanopore sequencing chemistry and atomic-level structures of various novel membrane protein nanopores. Combined with technologies such as nucleic acid chemistry, protein engineering, artificial membrane construction and characterization, semiconductor integrated circuit chip design, deep learning, and genomics, it develops a new generation of sequencers for nucleic acids and other biopolymers based on biological nanopores, along with supporting reagents and consumables. The company is committed to advancing China's sequencing industry from the ground up, reducing sequencing costs, enabling sequencing technology to be widely adopted by medical institutions at all levels, transforming disease diagnosis and treatment models, safeguarding the health and lives of the Chinese population, and meeting the urgent needs of precision medicine in the era of big data.